Moderna Flu Vaccine Set for FDA Advisory Panel Review

Moderna's flu vaccine is set for FDA advisory panel review, with a hearing scheduled for June. The review comes as Moderna looks to gain approval for its mRNA-based flu shot. The exact date of the review has not been confirmed.

MRNA Moderna's mRNA-based seasonal influenza vaccine candidate has been scheduled for FDA advisory committee review in June, a key gating event before a possible Biologics License Application decision. The panel will examine efficacy, immunogenicity, and safety data, with attention to how the mRNA platform compares against incumbent egg-based and recombinant flu shots from SNY Sanofi and GSK GSK.

The hearing matters strategically because seasonal flu is Moderna's clearest path to a second commercial product behind Spikevax, and an approval would validate the mRNA platform beyond COVID-19. Pivotal data have shown favorable immune responses against multiple strains, though regulators will probe relative efficacy versus established comparators, especially in older adults.

A positive advisory vote would put Moderna on track for a fall 2026 launch ahead of the next flu season, an important top-line catalyst as COVID revenue continues to decline. A negative or split vote, by contrast, would delay diversification and reinforce bear-case concerns about post-pandemic execution.

Related Stocks

MRNA